7/25/2023 0 Comments Dr brian schwartz![]() Ilaria progressed through increasingly senior leadership roles in the global clinical development of over 20 drug candidates during 12 years at Eli Lilly and Company, resulting in Fast Track and Breakthrough Designations and accelerated approvals, and provided medical support for global regulatory submissions as well as launch and post-launch activities. He was previously Executive Medical Director, Global Clinical Research and Development at Celgene and Program Lead Physician for the PD-1 inhibitor tislelizumab partnership with BeiGene. Ilaria joins Infinity from Bristol Myers Squibb where he was most recently the CTLA-4 Development Program Leader. Perkins added, “We are tremendously grateful for Brian’s impactful contributions across our clinical programs through key data readouts that pave the way for future development and are delighted he will be joining the Infinity Board of Directors to provide continued strategic insight as we plan for a registration study in bladder cancer and determine the best path forward in triple negative breast cancer based on maturing data to be presented by year end.”ĭr. I’m thrilled to continue contributing to the development of eganelisib in the capacity of a board member and look forward to working with Robert to ensure a seamless transition as he takes the helm of clinical development at Infinity.” These data, along with the demonstrated ability to overcome resistance to checkpoint inhibition in patients with melanoma and squamous cell cancer of the head and neck cancer, show consistent patient benefit and on-mechanism immune modulation with eganelisib across some of the most challenging patient populations and clinical settings. Schwartz said, “During my time leading eganelisib’s development, I have been extremely encouraged by the data generated from MARIO-275, MARIO-3 and MARIO-1, which demonstrate notable improvements in overall survival and progression free survival in bladder cancer and initial evidence of durable clinical activity in triple negative breast cancer. I look forward to working to advance eganelisib in registration enabling studies to leverage the benefit shown for patients with urothelial cancer and triple negative breast cancer, including in patients who are PD-L1 negative for whom treatment options are limited.”ĭr. These eganelisib data underscore the importance of reprogramming macrophages in the tumor microenvironment to improve outcomes for patients with some of the greatest unmet needs in solid tumors. Ilaria said, “I’m thrilled to join Infinity at this important time in the development of eganelisib given the strength of the data generated to date across multiple indications and treatment settings which provide strong evidence that eganelisib has the potential to be a transformative therapy in immuno-oncology. “Robert’s extensive experience in drug development will be critically important as we build upon the compelling eganelisib data presented over the last year and initiate future studies to maximize eganelisib’s considerable potential.”ĭr. ![]() ![]() “Robert’s deep expertise in oncology drug development, with a focus in immuno-oncology – most recently leading the Celgene/BeiGene PD-1 inhibitor collaboration and Bristol Myers Squibb’s CTLA-4 program, will be a tremendous asset to Infinity at this exciting point in the trajectory of eganelisib’s development,” said Adelene Perkins, Chief Executive Officer and Chair, Infinity Pharmaceuticals. In addition, Brian Schwartz, M.D., will be transitioning from his role as Consulting Chief Physician to the Infinity Board of Directors. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer, today announced the appointment of Robert Ilaria, Jr., M.D. CAMBRIDGE, Mass.-( BUSINESS WIRE)- Infinity Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |